Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3071 |
Name | gliosarcoma |
Definition | A gliomablastoma that is characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma gliosarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602667 | Phase I | Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Active, not recruiting | USA | AUS | 0 |
NCT00669669 | Phase Ib/II | O6-benzylguanine Carmustine + Filgrastim + Plerixafor + Temozolomide | Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas | Terminated | USA | 0 |
NCT00998010 | Phase II | Bortezomib + Temozolomide | Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | Completed | USA | 0 |
NCT01130077 | Phase I | Poly ICLC | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas | Completed | USA | 0 |
NCT01149850 | Phase II | Bevacizumab + Temozolomide | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | Completed | USA | 0 |
NCT01260506 | Phase Ib/II | Bevacizumab + VB-111 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | Completed | USA | ISR | 0 |
NCT01266031 | Phase Ib/II | Bevacizumab + Vorinostat Bevacizumab | Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01339039 | Phase I | Bevacizumab + Plerixafor | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | Terminated | USA | 0 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | BEL | 0 |
NCT01430351 | Phase I | Metformin + Temozolomide Mefloquine + Temozolomide Memantine + Metformin + Temozolomide Mefloquine + Memantine + Temozolomide Mefloquine + Memantine + Metformin + Temozolomide Temozolomide Mefloquine + Metformin + Temozolomide Memantine + Temozolomide | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | Active, not recruiting | USA | 0 |
NCT01434602 | Phase Ib/II | Everolimus + Sorafenib | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | Completed | USA | 0 |
NCT01435395 | Phase I | Bevacizumab + Bortezomib + Temozolomide | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme | Completed | USA | 0 |
NCT01591577 | Phase II | Lapatinib + Temozolomide | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme | Completed | USA | 0 |
NCT01721577 | Phase Ib/II | AXL1717 | Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas | Terminated | USA | 0 |
NCT01730950 | Phase II | Bevacizumab | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01753713 | Phase II | Dovitinib | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | Completed | USA | 0 |
NCT01790503 | Phase Ib/II | Pexidartinib Temozolomide | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT01837862 | Phase Ib/II | Carboplatin + Mebendazole + Temozolomide + Vincristine Sulfate Bevacizumab + Irinotecan + Mebendazole | A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas | Completed | USA | 0 |
NCT01894061 | Phase II | Bevacizumab | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01903330 | Phase II | Bevacizumab Cyclophosphamide Sargramostim | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT01931098 | Phase II | Pazopanib + Topotecan | Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM) | Completed | USA | 0 |
NCT01977677 | Phase Ib/II | Temozolomide Plerixafor | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | Completed | USA | 0 |
NCT01989052 | Phase Ib/II | Lomustine Carboxyamidotriazole Orotate | Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | Terminated | USA | 0 |
NCT02052648 | Phase Ib/II | Temozolomide Indoximod | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | Completed | USA | 0 |
NCT02062827 | Phase I | M032 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (M032-HSV-1) | Active, not recruiting | USA | 0 |
NCT02078648 | Phase Ib/II | SL-701 Poly ICLC Bevacizumab | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | Completed | USA | 0 |
NCT02101905 | Phase I | Lapatinib | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | Completed | USA | 0 |
NCT02133183 | Phase I | Sapanisertib | TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02137759 | Phase II | Vorinostat Temozolomide | MRSI to Predict Response to RT/TMZ and Vorinostat in GBM | Active, not recruiting | USA | 0 |
NCT02152982 | Phase II | Veliparib Temozolomide | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Active, not recruiting | USA | 1 |
NCT02197169 | Phase I | DNX-2401 DNX-2401 + Interferon gamma | DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) | Completed | USA | 0 |
NCT02238496 | Phase II | Perifosine + Temsirolimus | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Completed | USA | 0 |
NCT02287428 | Phase I | NeoVax Pembrolizumab Temozolomide NeoVax + Pembrolizumab + Temozolomide NeoVax + Pembrolizumab | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM | Recruiting | USA | 0 |
NCT02311920 | Phase I | Temozolomide Nivolumab Ipilimumab | Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Completed | USA | 0 |
NCT02337491 | Phase II | Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab +/- Bevacizumab for Recurrent GBM | Completed | USA | 0 |
NCT02340156 | Phase II | SGT-53 Temozolomide | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | Terminated | USA | 1 |
NCT02386826 | Phase I | Bevacizumab + Capmatinib | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | Completed | USA | 0 |
NCT02521090 | Phase Ib/II | EGFRBi-armed autologous activated T cells | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | Withdrawn | 0 | |
NCT02607124 | Phase Ib/II | Ribociclib | Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Terminated | USA | 0 |
NCT02626364 | Phase II | Crenolanib | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | Completed | USA | 0 |
NCT02648633 | Phase I | Nivolumab + Valproic acid | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02658981 | Phase I | Relatlimab Urelumab Nivolumab + Urelumab Nivolumab + Relatlimab | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | Completed | USA | 0 |
NCT02661282 | Phase Ib/II | Autologous CMV-specific CTLs + Temozolomide | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | Completed | USA | 0 |
NCT02743078 | Phase II | Bevacizumab | Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02798406 | Phase II | DNX-2401 + Pembrolizumab | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE) | Completed | USA | CAN | 0 |
NCT02852655 | Phase 0 | Pembrolizumab | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | Active, not recruiting | USA | 0 |
NCT02871843 | Phase I | RRx-001 + Temozolomide | Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) | Completed | USA | 0 |
NCT02942264 | Phase Ib/II | Zotiraciclib Temozolomide + Zotiraciclib | TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | Completed | USA | 0 |
NCT02977780 | Phase II | CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | Recruiting | USA | 0 |
NCT03027388 | Phase I | LB-100 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | Completed | USA | 0 |
NCT03107780 | Phase I | KRT-232 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | Suspended | USA | 0 |
NCT03139916 | Phase II | Bavituximab + Temozolomide | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
NCT03174197 | Phase Ib/II | Atezolizumab + Temozolomide | Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) | Active, not recruiting | USA | 0 |
NCT03197506 | Phase II | Pembrolizumab + Temozolomide Pembrolizumab | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | Active, not recruiting | USA | 0 |
NCT03277638 | Phase Ib/II | Pembrolizumab | Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT03344250 | Phase I | EGFRBi-armed autologous activated T cells | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT03367715 | Phase II | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | Completed | USA | 0 |
NCT03426891 | Phase I | Pembrolizumab + Temozolomide + Vorinostat | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT03452930 | Phase I | Tinostamustine | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | Completed | USA | 0 |
NCT03532295 | Phase II | Bevacizumab + Epacadostat + Radiotherapy + Retifanlimab Bevacizumab + Radiotherapy + Retifanlimab | INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas | Active, not recruiting | USA | 0 |
NCT03641326 | Phase II | Sunitinib | Sunitinib in Sarcomas of the Central Nervous System | Terminated | USA | 0 |
NCT03657576 | Phase I | C134-HSV-1 | Trial of C134 in Patients With Recurrent GBM (C134-HSV-1) | Active, not recruiting | USA | 0 |
NCT03681028 | Phase I | Feasibility of Individualized Therapy for Recurrent GBM | Active, not recruiting | USA | 0 | |
NCT03707457 | Phase I | Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | Terminated | USA | 0 |
NCT03714334 | Phase I | DNX-2440 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Terminated | ESP | 0 |
NCT03856099 | Phase II | Tanibirumab | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | Terminated | USA | AUS | 0 |
NCT03896568 | Phase I | DNX-2401 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Recruiting | USA | 0 |
NCT03961971 | Phase I | Sabatolimab + Spartalizumab | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | Active, not recruiting | USA | 0 |
NCT03965494 | Phase I | Bemcentinib | AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery | Terminated | USA | 0 |
NCT03970447 | Phase II | Lomustine Regorafenib Temozolomide | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) | Recruiting | USA | FRA | DEU | CHE | CAN | AUS | 0 |
NCT04013672 | Phase II | Montanide ISA 51 + Pembrolizumab + Sargramostim + SurVaxM | Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | Completed | USA | 0 |
NCT04051606 | Phase II | Regorafenib | Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT04195139 | Phase II | Nivolumab + Temozolomide Temozolomide | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG) | Active, not recruiting | USA | AUS | 0 |
NCT04216329 | Phase I | Selinexor + Temozolomide | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT04225039 | Phase II | INCAGN01876 + Retifanlimab | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT04254419 | Phase I | Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas | Not yet recruiting | USA | 0 | |
NCT04396860 | Phase II | Temozolomide Ipilimumab + Nivolumab | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT04406272 | Phase II | Bevacizumab + VB-111 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | Terminated | USA | 0 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04555577 | Phase I | Peposertib Temozolomide | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | Recruiting | USA | 0 |
NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Active, not recruiting | USA | 0 |
NCT04681677 | Phase II | Bevacizumab | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT) | Terminated | USA | 0 |
NCT04691960 | Phase II | Metformin | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | Recruiting | USA | 0 |
NCT04817254 | Phase II | Ipilimumab + Nivolumab + Temozolomide | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Recruiting | USA | 0 |
NCT04854044 | Phase I | ONC201 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT05039281 | Phase Ib/II | Atezolizumab + Cabozantinib | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05052957 | Phase II | Carmustine + Filgrastim + O6-benzylguanine + Temozolomide | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM) | Recruiting | USA | 0 |
NCT05074992 | Phase II | Ipilimumab | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma (NeAT Glio) | Terminated | GBR | 0 |
NCT05083754 | Phase I | Retifanlimab Temozolomide Retifanlimab + Temozolomide | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | Recruiting | USA | 0 |
NCT05084430 | Phase Ib/II | M032 + Pembrolizumab | Study of Pembrolizumab and M032 (NSC 733972) | Recruiting | USA | 0 |
NCT05120960 | Phase I | Tepotinib Osimertinib + Tepotinib | A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors | Withdrawn | 0 | |
NCT05284643 | Phase 0 | Bevacizumab | Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib w TMZ for rGBM | Recruiting | USA | 0 |
NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05474378 | Phase I | Retroviral vector transduced B7-H3 CAR T cells | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | Recruiting | USA | 0 |
NCT05503797 | Phase II | Cobicistat + PLX8394 PLX8394 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05698524 | Phase I | Abexinostat + Temozolomide | A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma | Recruiting | USA | 0 |
NCT05879120 | Phase II | Pembrolizumab | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT05887882 | Phase I | TGF-beta-imprinted NK cells | Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors (PNOC028) | Recruiting | USA | 0 |
NCT06011109 | Phase Ib/II | Bevacizumab APG-157 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Recruiting | USA | 0 |
NCT06095375 | Phase I | Regorafenib + Temozolomide | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) | Recruiting | ITA | 0 |
NCT06193174 | Phase I | C134-HSV-1 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | Not yet recruiting | USA | 0 |
NCT06297512 | Phase II | Doxorubicin + Temozolomide | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | Recruiting | ITA | 0 |
NCT06463184 | Phase I | Xevinapant | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | Withdrawn | 0 | |
NCT06501911 | Phase I | Bicalutamide | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | Not yet recruiting | USA | 0 |
NCT06614855 | Phase I | C134-HSV-1 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | Not yet recruiting | USA | 0 |